Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01897532
First received: July 9, 2013
Last updated: November 21, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2018
  Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)